200 mg/m2 melphalan as initial therapy in multiple myeloma:: A key to rapid achievement of complete remission.

被引：0
|
作者：
Powles, R
Sirohi, B
Singhal, S
Goyal, S
Treleaven, J
Lloyd, C
Kulkarni, S
Mehta, J
机构：
[1] Royal Marsden Hosp, Surrey, England
[2] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5374
引用
收藏
页码：397B / 397B
页数：1
相关论文
共 50 条
  • [1] 200 mg/m2 melphalan—the gold standard for multiple myeloma
    Sergio Giralt
    Nature Reviews Clinical Oncology, 2010, 7 : 490 - 491
  • [2] 200 mg/m2 melphalan-the gold standard for multiple myeloma
    Giralt, Sergio
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 490 - 491
  • [3] Melphalan 200 mg/m2 versus 100 mg/m2 in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Lauta, V. M.
    Montanaro, M.
    Cangialosi, C.
    Morandi, S.
    D'Agostino, F.
    Cavallo, F.
    Omede, P.
    Musto, P.
    Foue, R.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 189 - 189
  • [4] Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
    Ludwig, Heinz
    Spicka, Ivan
    Linkesch, Werner
    Greil, Richard
    Kasparu, Hedwig
    Gunsilius, Eberhard
    Thaler, Josef
    Drach, Johannes
    Kuhn, Ingrid
    Weissmann, Adalbert
    Hinke, Axel
    BLOOD, 2008, 112 (11) : 1139 - 1139
  • [5] COMPARISON OF BUSULFAN plus MELPHALAN TO MELPHALAN 200 MG/M2 AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
    Ahmed, S.
    Dinh, Y.
    Rondon, G.
    Andersson, B.
    Jones, R.
    Bashir, Q.
    Shah, N.
    Popat, U.
    Champlin, R. E.
    Qazilbash, M. H.
    Kebriaei, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S251 - S251
  • [6] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [7] In myeloma patients treated with melphalan 100mg/m2 or melphalan 200mg/m2 outcome is not significantly different.
    Palumbo, A
    Triolo, S
    Bringhen, S
    Rus, C
    Omedè, P
    Bertola, A
    Giaccone, L
    Bianchi, A
    Bruno, B
    Tarella, C
    Caravita, T
    Musto, P
    Amadori, S
    Carotenuto, M
    Pileri, A
    Boccadoro, M
    BLOOD, 2000, 96 (11) : 419A - 419A
  • [8] Multiple myeloma: a comparison of two melphalan conditioning regimens (200 mg/m2 versus 140 mg/m2) for autologous stem cell transplantation
    Julve, M.
    Hassan, S.
    Matthews, J.
    Farrell, M.
    Guy, A.
    Popat, R.
    Smith, M.
    Oakervee, H.
    Gribben, J.
    Cavenagh, J.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S226 - S227
  • [9] Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
    Palumbo, Antonio
    Bringhen, Sara
    Bruno, Benedetto
    Falcone, Antonietta Pia
    Liberati, Anna Marina
    Grasso, Mariella
    Ria, Roberto
    Pisani, Francesco
    Cangialosi, Clotilde
    Caravita, Tommaso
    Levi, Anna
    Meloni, Giovanna
    Nozza, Andrea
    Pregno, Patrizia
    Gabbas, Attilio
    Callea, Vincenzo
    Rizzo, Manuela
    Annino, Luciana
    De Stefano, Valerio
    Musto, Pellegrino
    Baldi, Ileana
    Cavallo, Federica
    Petrucci, Maria Teresa
    Massaia, Massimo
    Boccadoro, Mario
    BLOOD, 2010, 115 (10) : 1873 - 1879
  • [10] Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
    Brioli, Annamaria
    vom Hofe, Felix
    Rucci, Paola
    Ernst, Thomas
    Yomade, Olaposi
    Hilgendorf, Inken
    Scholl, Sebastian
    Sayer, Herbert
    Muegge, Lars-Olof
    Hochhaus, Andreas
    von Lilienfeld-Toal, Marie
    BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1209 - 1212
12345